Halozyme Therapeutics Inc (HALO)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 84.30% | 76.80% | 78.90% | 81.64% | 83.79% |
| Operating profit margin | 54.32% | 40.71% | 40.53% | 62.24% | 53.91% |
| Pretax margin | 54.87% | 42.01% | 37.71% | 56.06% | 48.32% |
| Net profit margin | 43.74% | 33.96% | 30.62% | 90.84% | 48.24% |
Halozyme Therapeutics Inc's profitability ratios show a fluctuating trend over the years. The gross profit margin, which indicates the percentage of revenue retained after accounting for cost of goods sold, decreased from 83.79% in 2020 to 76.80% in 2023 before increasing to 84.30% in 2024.
The operating profit margin, reflecting the efficiency of the company in managing its operating expenses, saw a significant increase from 53.91% in 2020 to 62.24% in 2021, followed by a decline to 40.53% in 2022, and then a slight recovery to 54.32% in 2024.
The pretax margin, which gauges the company's profitability before taxes, experienced fluctuations, starting at 48.32% in 2020, reaching its peak at 56.06% in 2021, dropping to 37.71% in 2022, and then rebounding to 54.87% in 2024.
The net profit margin, which signifies the percentage of revenue that remains as net income, surged from 48.24% in 2020 to a high of 90.84% in 2021, before declining to 30.62% in 2022, and then showing improvements to 43.74% in 2024.
Overall, while the company experienced fluctuations in profitability margins, especially in 2022, it managed to improve its profitability in 2024 compared to 2023. Further analysis of the underlying factors contributing to these changes would provide a more detailed understanding of Halozyme Therapeutics Inc's financial performance.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 26.73% | 19.48% | 14.53% | 24.98% | 24.87% |
| Return on assets (ROA) | 21.52% | 16.25% | 10.98% | 36.46% | 22.26% |
| Return on total capital | 158.11% | 438.01% | 156.58% | 140.09% | 95.50% |
| Return on equity (ROE) | 122.06% | 336.00% | 119.04% | 204.47% | 85.46% |
Halozyme Therapeutics Inc has shown strong profitability based on the provided ratios. The Operating Return on Assets (Operating ROA) has remained relatively high and stable over the past five years, ranging from 14.53% to 26.73%. This indicates the company's ability to generate operating profits relative to its total assets.
Similarly, the Return on Assets (ROA) has also been quite healthy, ranging from 10.98% to 36.46% over the same period. This ratio reflects the company's overall ability to generate profits from its assets.
The Return on Total Capital has been notably high, with a significant increase from 95.50% in 2020 to 438.01% in 2023, before moderating to 158.11% in 2024. This suggests that the company has efficiently utilized both debt and equity in generating returns for its capital providers.
Furthermore, the Return on Equity (ROE) has displayed a remarkable performance, with values fluctuating between 85.46% and 336.00% during the five-year period. This indicates the company's ability to generate profits for its shareholders based on their equity investments.
Overall, the profitability ratios of Halozyme Therapeutics Inc demonstrate strong performance, reflecting effective management of assets, capital, and equity to generate returns for the company and its stakeholders.